This perspective explores the practice implications for managing patients living with obesity and/or diabetes who are taking GLP-1 agonists by describing the impact of GLP-1 agonists; the challenges of GLP-1 agonist use; and the considerations for recommending physical activity to patients using these medications. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.